HIV and noncommunicable diseases: The Asian perspective

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue SUPPL.1, 2014, Pages

  Ananworanich, Jintanat ^a,b   Avihingsanon, Anchalee ^c,d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Asia; HIV; HIV associated neurocognitive disorders; kidney disease; non Hodgkin lymphoma; noncommunicable diseases

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; TENOFOVIR;

ANAL DYSPLASIA; ANUS DISEASE; ARTICLE; ASIA; BODY WEIGHT; CHRONIC KIDNEY DISEASE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; GENOTYPE; HEART MUSCLE ISCHEMIA; HEPATITIS B; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; MEN WHO HAVE SEX WITH MEN; METABOLIC DISORDER; NON COMMUNICABLE DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; WART VIRUS;

AIDS DEMENTIA COMPLEX; AIDS-ASSOCIATED NEPHROPATHY; ANTI-RETROVIRAL AGENTS; ASIA; COMORBIDITY; DEVELOPING COUNTRIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS;

EID: 84906070312     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000262     Document Type: Article

References (85)

1. UNAIDS. HIV in Asia and the Pacific: UNAIDS Report 2013. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/ 2013/2013-HIV-Asia-Pacific-en.pdf. Accessed April 5, 2014.
2. World Health Organization. Action plan for the prevention and control of noncommunicable disease in South-East Asia, 2013-2020. Available at: http://www.searo.who.int/entity/noncommunicable-diseases/documents/ sea-ncd-89(reduced).pdf. Accessed April 4, 2014.
3. Dans A, Ng N, Varghese C, et al. The rise of chronic non-communicable diseases in Southeast Asia: time for action. Lancet. 2011;377:680-689.
4. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129-2140.
5. Gujral UP, Pradeepa R, Weber MB, et al. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281:51-63.
6. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681-1688.
7. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA. 2007;297:286-294.
8. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640-1649.
9. Lo YC, Chen MY, Sheng WH, et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretro-viral therapy in Taiwan: a case-control study. HIV Med. 2009;10: 302-309.
10. Tseng CH, Tseng CP, Chong CK, et al. Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort. Diabetologia. 2006;49:1755-1760.
11. Kerr SJ, Duncombe C, Avihingsanon A, et al. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic). 2007; 6:36-46.
12. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005;39:199-202.
13. Han SH, Zhou J, Saghayam S, et al. Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr J. 2011; 58:475-484.
14. Autar RS, Ananworanich J, Apateerapong W, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother. 2004;54:785-790.
15. Autar RS, Boffito M, Hassink E, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother. 2005;56:908-913.
16. Avihingsanon A, van der Lugt J, Kerr SJ, et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther. 2009;85:402-408.
17. Dickinson L, Boffito M, Back DJ, et al. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother. 2008;62:1344-1355.
18. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20:131-132.
19. van der Lugt J, Avihingsanon A. Clinical pharmacology and pharmaco-kinetics of antiretrovirals in Asia. Asian Biomed. 2009;3:53-62.
20. van der Lugt J, Lange J, Avihingsanon A, et al. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. Antivir Ther. 2009;14:1001-1004.
21. Kim HS, Chin BS, Shin HS. Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine. J Korean Med Sci. 2013;28:827-832.
22. Avihingsanon A, Apornpong T, Ramautarsing RA, et al. Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy. Antivir Ther. 2014;19:41-49.
23. Choe PG, Choi HJ, Kim NH, et al. High prevalence of low bone mass and associated factors in Korean HIV-positive male patients undergoing antiretroviral therapy. J Int AIDS Soc. 2014;17:18773.
24. Poudel-Tandukar K, Poudel KC, Jimba M, et al. Serum 25-hydroxyvitamin d levels and C-reactive protein in persons with human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 2013;29: 528-534.
25. Puthanakit T, Saksawad R, Bunupuradah T, et al. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;61:477-483.
26. Wiboonchutikul S, Sungkanuparph S, Kiertiburanakul S, et al. Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting. J Int Assoc Physicians AIDS Care (Chic). 2012;11:305-310.
27. Ali MH, Magee MJ, Dave JA, et al. HIV and metabolic, body, and bone disorders: what we know from low-and middle-income countries. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S27-S39.
28. Cao Y, Gong M, Han Y, et al. Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naive patients in mainland China: a multicenter cross-sectional study. Nephrology (Carlton). 2013;18:307-312.
29. Cheung CY, Wong KM, Lee MP, et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol Dial Transplant. 2007;22:3186-3190.
30. Pujari SN, Smith C, Makane A, et al. Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom. BMC Infect Dis. 2014;14:173.
31. Yanagisawa N, Ando M, Ajisawa A, et al. Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract. 2011;118:c285-C291.
32. Kiertiburanakul S, Chaisiri K, Kasettratat N, et al. Monitoring of renal function among HIV-infected patients receiving tenofovir in a resource-limited setting. J Int Assoc Physicians AIDS Care (Chic). 2011;10:297-302.
33. Mizushima D, Tanuma J, Kanaya F, et al. WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients. PLoS One. 2013;8:e79885.
34. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6:e22661.
35. Praditpornsilpa K, Avihingsanon A, Chaiwatanarat T, et al. Comparisons between validated estimated glomerular filtration rate equations and iso-topic glomerular filtration rate in HIV patients. AIDS. 2012;26:1781-1788.
36. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996;38(suppl 2):S18-S23.
37. Fibriani A, Wisaksana R, Alisjahbana B, et al. Hepatitis B virus prevalence, risk factors and genotype distribution in HIV infected patients from West Java, Indonesia. J Clin Virol. 2014;59:235-241.
38. Quan VM, Go VF, Nam le V, et al. Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care. 2009;21:7-16.
39. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494-1498.
40. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol. 2004;72:363-369.
41. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48:1062-1069.
42. Matthews GV, Seaberg EC, Avihingsanon A, et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis. 2013;56:e87-e94.
43. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014. Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed April 18, 2014.
44. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-1342.
45. Ye S, Pang L, Wang X, et al. Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia. Curr HIV/AIDS Rep. 2014;11:128-133.
46. Nishijima T, Shimbo T, Komatsu H, et al. Incidence and risk factors for incident Hepatitis C infection among men who have sex with men with HIV-1 infection in a large Urban HIV clinic in Tokyo. J Acquir Immune Defic Syndr. 2014;65:213-217.
47. van Griensven J, Phirum L, Choun K, et al. Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia. PLoS One. 2014;9:e88552.
48. Dunford L, Carr MJ, Dean J, et al. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One. 2012;7:e39027.
49. Maek-A-Nantawat W, Avihingsanon A, Ohata PJ. Challenges in providing treatment and care for viral hepatitis among individuals co-infected with HIV in resource-limited settings. AIDS Res Treat. 2012;2012:948059.
50. Chalermchai T, Valcour V, Sithinamsuwan P, et al. Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol. 2013;19:137-143.
51. Wang J, Kou H, Fu Q, et al. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. PLoS One. 2011;6:e26739.
52. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr. 2006;41:53-58.
53. Zhang C, Wang W, Zhou M, et al. The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted. J Acquir Immune Defic Syndr. 2013;62:540-545.
54. Bunupuradah T, Chetchotisakd P, Jirajariyavej S, et al. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy. J Neu-rovirol. 2012;18:479-487.
55. Pumpradit W, Ananworanich J, Lolak S, et al. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol. 2010;16:76-82.
56. Zhang Y, Qiao L, Ding W, et al. An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China. J Neurovirol. 2012;18:120-126.
57. Joseph J, Achim CL, Boivin MJ, et al. Global NeuroAIDS roundtable. J Neurovirol. 2013;19:1-9.
58. Tyor W, Fritz-French C, Nath A. Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders. J Neuro-virol. 2013;19:515-522.
59. Sailasuta N, Ross W, Ananworanich J, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One. 2012;7:e49272.
60. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275-282.
61. Shiramizu B, Ananworanich J, Chalermchai T, et al. Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. J Neu-rovirol. 2012;18:69-73.
62. Chibanda D, Benjamin L, Weiss HA, et al. Mental, neurological and substance use disorders in people living with HIV/AIDS in low-and middle-income countries. J Acquir Immune Defic Syndr. 2014;67(suppl 1):S54-S67.
63. Heaps J, Valcour V, Chalermchai T, et al. Development of normative neuro-psychological performance in Thailand for the assessment of HIV-associated neurocognitive disorders. J Clin Exp Neuropsychol. 2013;35:1-8.
64. Rungreangkulkij S, Wongtakee W. The psychological impact of Buddhist counseling for patients suffering from symptoms of anxiety. Arch Psychiatr Nurs. 2008;22:127-134.
65. Gonzalez-Garcia M, Ferrer MJ, Borras X, et al. Effectiveness of mindfulness-based cognitive therapy on the quality of life, emotional status, and CD4 cell count of patients aging with HIV infection. AIDS Behav. 2014;18:676-685.
66. Tan LF, Dienes Z, Jansari A, et al. Effect of mindfulness meditation on brain-computer interface performance. Conscious Cogn. 2014;23:12-21.
67. Hejazi N, Huang MS, Lin KG, et al. Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia. Glob J Health Sci. 2014;6:58-71.
68. Carr A, Grund B, Neuhaus J, et al. Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS. 2008;22:257-267.
69. Guha S, Pande A, Mookerjee S, et al. Echocardiographic profile of ART naive human immunodeficiency virus (HIV) infected patients in a tertiary care hospital in Kolkata. Indian Heart J. 2010;62:330-334.
70. Luo L, Ye Y, Liu Z, et al. Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China. Int J STD AIDS. 2010;21:814-818.
71. Edwards-Jackson N, Kerr S, Tieu H, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med. 2011; 12:510-515.
72. Kiertiburanakul S, Likhitpongwit S, Ratanasiri S, et al. Malignancies in HIV-infected Thai patients. HIV Med. 2007;8:322-323.
73. Yang CJ, Chen MY, Hsieh SM, et al. Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan. J Mi-crobiol Immunol Infect. 2010;43:278-284.
74. Chung CY, Park SW, Myung E, et al. AIDS-related gastrointestinal kaposi sarcoma in Korea: a case report and review of the literature. Korean J Gastroenterol. 2012;60:166-171.
75. Katano H, Yokomaku Y, Fukumoto H, et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus among men who have sex with men in Japan. J Med Virol. 2013;85:1046-1052.
76. Yanagimoto S, Yotsuyanagi H, Kikuchi Y, et al. Chronic hepatitis B in patients coinfected with human immunodeficiency virus in Japan: a retrospective multicenter analysis. J Infect Chemother. 2012;18:883-890.
77. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010; 11:827-834.
78. Chen YC, Liu HY, Li CY, et al. Low Papanicolaou smear screening rate of women with HIV infection: a nationwide population-based study in Taiwan, 2000-2010. J Womens Health (Larchmt). 2013;22: 1016-1022.
79. Joshi S, Sankaranarayanan R, Muwonge R, et al. Screening of cervical neoplasia in HIV-infected women in India. AIDS. 2013;27:607-615.
80. Couture MC, Page K, Stein ES, et al. Cervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection. BMC Infect Dis. 2012;12:166.
81. Phanuphak N, Teeratakulpisarn N, Triratanachat S, et al. High prevalence and incidence of high-grade anal intraepithelial neoplasia among young Thai men who have sex with men with and without HIV. AIDS. 2013;27: 1753-1762.
82. Yang Y, Li X, Zhang Z, et al. Association of human papillomavirus infection and abnormal anal cytology among HIV-infected MSM in Beijing, China. PLoS One. 2012;7:e35983.
83. Nguyen K, Van Nguyen T, Shen D, et al. Prevalence and presentation of hepatitis B and C virus (HBV and HCV) infection in Vietnamese Americans via serial community serologic testing. J Immigr Minor Health. 2014. [ePub ahead of print, January 29, 2014].
84. Richter C, Ter Beest G, Gisolf EH, et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands. Epidemiol Infect. 2014;1-7. [ePub ahead of print, January 7, 2014]
85. Van den Berg E, Hospers FA, Navis G, et al. Dietary acid load and rapid progression to end-stage renal disease of diabetic nephropathy in Westernized South Asian people. J Nephrol. 2011;24:11-17.